Executive Director of General Medical Biology
Shelly Meeusen, Ph.D.,
Dr. Meeusen currently serves as Executive Director of General Medical Biology at the Genomics Institute of the Novartis Research Foundation (GNF), where she is responsible for drug discovery biology in the general medical area at the Institute. She oversees the drug discovery efforts of approximately 115 scientists, including 40 Ph.D.s. The team is focused on novel therapeutic discovery in the areas of regenerative medicine (including respiratory, musculoskeletal, cardiac, and renal biology), as well as the molecular targeted drug delivery and RNA targeted drug discovery initiatives. Since joining GNF in 2009, she has directly contributed to 5 clinical candidates in the regenerative medicine and auto-immune disease space. Before joining GNF, she helped build research capabilities for The Jackson Laboratory’s northern California site. As Director of In Vivo Research Services, she evaluated mechanisms and therapeutic potential for more than 30 clinical candidates in diverse therapeutic areas: auto-immune diseases, oncology, pain, cardiovascular, metabolism, and neurodegeneration. Prior to the Jackson Laboratory, Dr. Meeusen researched neuro-inflammation and repair at the Institute for Pediatric Regenerative Medicine as a CIRM-funded post-doctoral fellow. She received her Ph.D. as an NIH grant recipient in Biochemistry and Molecular Biology at University of California, Davis where she was the first to reconstitute the mitochondrial fusion process in vitro, assigning function to genes responsible for multiple neurodegenerative diseases.